An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.
High-Risk and Oligometastatic Prostate Cancer
DRUG: Apalutamide
rPFS, radiographic progression-free survival, Change from Baseline at preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.
pCR, pathological complete response, preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.|PFS, positive margin rate; progression-free survival, preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.|PSA response rate:, more than 50% decrease from baseline, preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.|TTPP, time to PSA progression, preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.|time to BCR after surgery, preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.|pathological stage, preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.
The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.